At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 914 enrolled
Drug / intervention
Vonoprazan +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Efficacy and Safety of Vonoprazan- Amoxicillin Dual Therapy for Helicobacter Pylori Eradication : a Prospective, Multicenter, Randomized Controlled Trial
Nanjing First Hospital, Nanjing Medical University·interventional·Posted Jul 22, 2022·Updated Jun 13, 2024
In Brief
A Phase 4 clinical trial evaluating Vonoprazan and Amoxicillin for Helicobacter Pylori Infection. Completed, enrolled 914 participants across 10 sites.
Detailed Summary
The purpose of this study was to evaluate the Efficacy and Safety of Vonoprazan- amoxicillin dual therapy for Helicobacter Pylori eradication
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHelicobacter Pylori Infection
CountriesChina
Collaborators--
Timeline
Phase 4CompletedFinished
2023202420252026
First PostedJul 2022
Enrollment StartAug 2022
Primary CompletionAug 2023
Study CompletionSep 2023
TodayJul 2026
First PostedJul 22, 2022
Enrollment StartAug 1, 2022
Primary CompletionAug 31, 2023
Study CompletionSep 30, 2023
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 3.9 years ago
Interventions
Vonoprazandrug
Potassium-competitive acid blocker
Amoxicillindrug
Antibiotic for H. pylori eradication